---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-065289"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2023-03-09T23:59:59+00:00"
generated_at: "2026-06-18T07:26:25.958819+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cullinan Oncology reports Q4 net loss of $27.1M; licenses CLN-418; cash runway into 2026

## Summary
- Cash and investments $550.1M as of Dec 31, 2022; cash runway expected into 2026.
- Licensed U.S. rights to CLN-418 from Harbour Biomed for $25M upfront, up to $563M milestones plus royalties.
- Q4 net loss before noncontrolling interest $27.1M; full-year net income $109.2M due to gain on sale of Cullinan Pearl.
- IND clearance for CLN-978 (CD19xCD3) in Jan 2023; IND filed for CLN-617 (IL-12/IL-2) in Feb 2023.
- Initial clinical data for CLN-049 and CLN-619 expected mid-2023; pivotal study for zipalertinib initiated Q4 2022.

## SEC filing metadata
- accession: 0001193125-23-065289
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2023-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000119312523065289/0001193125-23-065289-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000119312523065289/d481993d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-065289
- JSON: https://secwatch.observer/filing/0001193125-23-065289.json
- Plain text: https://secwatch.observer/filing/0001193125-23-065289.txt

## Key facts
- Earnings Releases
  Cullinan Therapeutics, Inc. reported fourth quarter and full year ended December 31, 2022 results: net income 27.1 million.
  - Period: fourth quarter and full year ended December 31, 2022
  - Net income: 27.1 million
  - Result: reported results
  source text: Net loss (before items attributable to noncontrolling interest) for the fourth quarter of 2022 was $27.1 million, compared with net loss of $24.9 million for the third quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789972/000119312523065289/0001193125-23-065289-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.